|
Back to Home » August 2022 News » BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease |
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease |
August 23, 2022
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 RESEARCH TRIANGLE PARK, N.C. and PARIS, Aug. 23, 2022 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and...
Source URL: https://www.prnewswire.com:443/news-releases/brainvectis-a-subsidiary-of-askbio-receives-clearance-to-conduct-phase-iii-clinical-trial-in-france-for-its-novel-gene-therapy-for-early-stage-huntingtons-disease-301610417.html
|
|
|
|
